The global Real-World Evidence Solutions market was valued at USD 2.5 billion in 2023, is projected to experience sustained expansion through 2032. According to recent industry analysis, the market is forecasted to grow at a compound annual growth rate (CAGR) of 8.5%, reaching approximately USD 5.2 billion by the end of the forecast period.
This significant market growth underscores the increasing importance of real-world data (RWD) in shaping clinical, regulatory, and commercial decisions across the global healthcare ecosystem. As pharmaceutical companies, healthcare providers, and payers seek more evidence-driven insights, the demand for robust RWE tools and services is rising sharply.
Get a Sample Report of Real-World Evidence Solutions Market@ https://www.snsinsider.com/sample-request/1787
Drivers of Market Growth
Several key factors are contributing to the sustained upward trajectory of the RWE solutions market. Among them is the rising integration of digital health platforms, electronic health records (EHRs), and wearable technologies that enable the seamless capture of patient data in real-world settings. This shift from controlled clinical environments to more dynamic and representative data sources supports broader applicability and relevance of evidence generated.
Additionally, regulators including the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and other international agencies have increasingly embraced RWE to support decisions around drug approvals, safety monitoring, and post-marketing surveillance. The growing trust in real-world insights is paving the way for accelerated adoption of these solutions across the healthcare continuum.
Segment Insights
By Component: Services Segment Dominates the Market
In 2023, the services segment led the RWE solutions market, accounting for 57.6% of global revenue. This segment’s growth is fueled by the increasing reliance on end-to-end real-world services provided by leading companies like IQVIA, ICON plc, and Syneos Health. These services encompass everything from research planning and protocol development to clinical study execution and final reporting.
While services remain dominant, the data sets segment is expected to gain strong traction throughout the forecast period. The rising demand for insights into healthcare costs, treatment compliance, epidemiology, and patient behaviors is driving investment into expansive and well-structured RWD sources.
By Application: Drug Development and Approvals Take Center Stage
With a 26.7% market share in 2023, the drug development and approvals segment emerged as the most prominent application area for RWE solutions. Pharmaceutical companies increasingly utilize RWE to improve drug trial designs, manage clinical operations more efficiently, and accelerate the approval process.
The regulatory environment is also evolving in support of RWE. In December 2023, the U.S. Food and Drug Administration (FDA) released draft guidance detailing the use of RWD in evaluating medical devices. The reimbursement and regulatory decision-making segment is expected to register notable growth as agencies like the FDA create frameworks that formally incorporate RWE into clinical and payer decisions.
By Therapeutic Area: Oncology Leads with Robust Adoption
Oncology represented the largest share of the RWE market in 2023, contributing 29.0% of total revenue. This is largely attributed to the high global incidence of cancer and the urgent need for faster drug development and regulatory pathways. RWE enables pharmaceutical companies to cut costs associated with oncology trials and obtain faster market access.
According to GLOBOCAN, over 10 million new cancer cases were recorded globally in 2022. The demand for more efficient, targeted cancer treatments is driving widespread adoption of RWE solutions across pre-clinical, clinical, and post-market phases.
The cardiology segment is expected to register rapid growth due to the increasing burden of cardiovascular diseases and the growing availability of large-scale patient datasets for real-world analysis.
By End Use: Healthcare Companies Lead Adoption
Healthcare companies emerged as the dominant end-users in 2023, accounting for 35.0% of the market. These organizations rely on RWE to evaluate drug effectiveness, safety, and real-world performance post-approval.
A notable development was PINC AI Applied Sciences’ (PAS) extended partnership with Datavant in February 2024. This collaboration enhances data integration capabilities for clinical research, signaling the increasing focus on connected, longitudinal healthcare datasets.
The healthcare payers segment is poised for significant expansion due to the rising need for value-based pricing models and improved safety surveillance for pharmaceuticals and medical devices.
Regional Insights
North America continues to lead the global RWE solutions market, with over 43.5% of global revenue in 2023. This region benefits from a progressive regulatory landscape and growing investment in R&D and digital health infrastructure. Programs like the FDA’s Advancing Real-World Evidence Program support the integration of RWE in drug and device approvals, promoting innovation and market expansion.
Europe is projected to register steady growth due to factors such as aging populations, increased incidence of chronic illnesses, and higher healthcare spending. ICON plc’s acquisition of PRA Health Sciences has expanded its real-world capabilities, while Cegedim Health Data has grown its presence by including German healthcare datasets in its RWE offerings.
Asia-Pacific is forecast to be the fastest-growing regional market through 2032. Government-driven digital health reforms in countries like India and Japan are expected to significantly enhance RWE adoption. India’s National Digital Health Mission will play a key role in establishing the digital infrastructure necessary for collecting and utilizing real-world data. In Japan, local pharma companies are deploying RWE to improve patient outcomes and drive cost-efficiency.
Competitive Landscape
The Real-World Evidence Solutions Market is moderately consolidated, with key players actively pursuing strategic collaborations, acquisitions, and technological enhancements to maintain market position. Major players include:
- IQVIA Inc.
- ICON plc
- Syneos Health
- Oracle
- Medpace
- IBM
- Cognizant
- Optum Inc.
- Clinigen Limited
- PerkinElmer Inc.
- Cegedim Health Data
- PPD, Inc. (Now part of Thermo Fisher Scientific)
- Parexel International Corporation
- SAS Institute Inc.
Recent Strategic Developments
- April 2024: IQVIA expanded its strategic alliance with Salesforce to further develop the Life Sciences Cloud. The partnership aims to integrate RWE into broader healthcare decision-making processes, supporting functions like discovery, clinical development, medical affairs, and safety.
- April 2024: Parexel formed a strategic collaboration with Palantir Technologies Inc. to embed AI-driven analytics into clinical trial operations. This alliance strengthens Parexel’s capabilities in delivering data-driven RWE solutions for improved trial efficiency and health outcomes.
Conclusion
The Real-World Evidence Solutions Market is on a strong growth trajectory, driven by technological advancements, regulatory acceptance, and increasing demand for cost-effective healthcare innovation. As stakeholders across the value chain adopt RWE to support faster, safer, and more personalized healthcare decisions, the market is expected to double in size over the next decade.
Organizations seeking customized research or in-depth insights on the RWE landscape can explore SNS Insider’s latest report on the Real-World Evidence Solutions Market or contact our analysts directly for tailored research services.
Buy a Single-User PDF of Real-World Evidence Solutions Market Analysis & Outlook Report 2024-2032@ https://www.snsinsider.com/checkout/1787
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company’s aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
Contact Us:
Jagney Dave – Vice President of Client Engagement
Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)
Email: [email protected]
